One is the activation of the PI3K/AKT survival pathway due to mutational activation of PIK3CA or inactivation of PTEN [90], so PI3K inhibition enhances the anti-tumor effect of eribulin in triple-negative breast cancer [91]. The gene discussed is AKT1; the disease is triple-negative breast carcinoma.